ArticleFrontiers in immunology2021
IL-10 Deficiency Accelerates Type 1 Diabetes Development
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Innovative diabetes mellitus treatment strategies: Mesenchymal stem cell-based therapy and its impact on pro- and anti-inflammatory cytokines modulation.Journal of pharmaceutical analysis · 2026Review
- CU104, a novel barrier function enhancer, improves colitis via modulation of barrier function and immune cell recruitment.Frontiers in immunology · 2026Article
- Role of Interleukins in Type 1 and Type 2 Diabetes.Diagnostics (Basel, Switzerland) · 2025Review
- Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention.Nature reviews. Clinical oncology · 2025Review
- Toxoplasma gondii modulates immune responses and mitigates type 1 diabetes progression in a streptozotocin-induced rat model.Cell communication and signaling : CCS · 2025Article
- Sex-specific cytokine, chemokine, and growth factor signatures in T1D patients and progressors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Regulation of Tert methylation alleviates food allergy via regulating the Tert-IL10 signal pathway.Immunologic research · 2024Article
- Review
- In vitro immunoregulatory role of recombinant Ancylostoma ceylanicum calreticulin.Parasites, hosts and diseases · 2024Article
- Gut microbiota from B-cell-specific TLR9-deficient NOD mice promote IL-10Frontiers in immunology · 2024Article
- Article
- CD56 Expression in Spleen Tissue Pathology and Its Implications in the Development of Type 1 Diabetes: Insights from Diabetic Rat Models.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024Article
- Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- The Gut Microbiota of Pregnant Rats Alleviates Fetal Growth Restriction by Inhibiting the TLR9/MyD88 Pathway.Journal of microbiology and biotechnology · 2023Article
- The Relationship between Type 1 Diabetes Mellitus, TNF-α, and IL-10 Gene Expression.Biomedicines · 2023Article
- Emerging trends and focus on the link between gut microbiota and type 1 diabetes: A bibliometric and visualization analysis.Frontiers in microbiology · 2023Article
- Host gene effects on gut microbiota in type 1 diabetes.Biochemical Society transactions · 2022Review
- Immunological balance between Treg and Th17 lymphocytes as a key element of type 1 diabetes progression in children.Frontiers in immunology · 2022Article
- The Contribution of Neutrophils and NETs to the Development of Type 1 Diabetes.Frontiers in immunology · 2022Review
- The Impact of Intestinal Microorganisms and Their Metabolites on Type 1 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Juan HuangNational Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, China.
Qiyuan TanSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Ningwen TaiSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
James Alexander PearsonSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Yangyang LiSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Chen ChaoNational Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, China.
Lucy ZhangSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Jian PengSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Yanpeng XingSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Luyao ZhangSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Youjia HuSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Zhiguang ZhouNational Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, China.
F Susan WongDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Li WenSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Yale University · USSecond Xiangya Hospital of Central South University · CNCardiff University · GBFirst Hospital of Jilin University · CNJilin University · CNShanghai Sixth People's Hospital · CN
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI Kevan C Herold, GERALD I SHULMAN · 1993 to 2026
$44.0MMedical Research Council MR/K021141Medical Research Council MR/T010525/1Medical Research Council MR/T10525NCATS NIH HHS UL1 TR001863NIDDK NIH HHS P30 DK045735
Abstract
Type 1 diabetes is an autoimmune disease caused by T cell-mediated destruction of insulin-producing β cells.
Indexed as
Adaptive ImmunityImmunity, InnateAnimalsDiabetes Mellitus, Type 1Gastrointestinal MicrobiomeInterleukin-10MiceMice, Inbred NODMice, KnockoutT-Lymphocytes, RegulatoryIL10 protein, mouseInterleukin-10CD4+ T cellsgut microbiotainterleukin-10neutrophilstype 1 diabetes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.